Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Lucentis recommended for approval in E.U. for wet AMD

Nov. 20, 2006

New agent for glaucoma disclosed in recent Johns Hopkins University patent

Nov. 15, 2006

SPI-0023: a novel ciclosporin formulation for ophthalmic use

Nov. 14, 2006

AzaSite Plus begins phase I safety study

Nov. 10, 2006

OcuCure uses seed funding to advance compounds for AMD

Nov. 10, 2006

CGC-11047 studied in patients with AMD

Nov. 10, 2006

Lux licenses ciclosporin-eluting silicone matrix ocular implant from NIH

Nov. 9, 2006

MacuSight's proprietary sirolimus formulation begins phase I study in wet AMD

Nov. 6, 2006

TG-100801 for ocular diseases studied in phase I

Nov. 3, 2006

Recent PhotoBioChem patent describes new porphyrin derivatives for AMD

Oct. 30, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...